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The aim of this study was to evaluate whether small left
ventricular (LV) volumes increase the negative prognostic
impact of a restrictive filling pattern (RFP) and that of mitral
regurgitation (MR) in patients with nonischemic heart failure
(HF). The Meta-analysis Research Group in Echocardiogra-
phy (MeRGE) is a meta-analysis that collated individual
patient data from several prospective echocardiography
outcome studies. This analysis was restricted to 10 studies
and 601 patients with nonischemic HF. The role of MR
was tested in a subgroup of 252 patients. A total of 106
deaths occurred during a median follow-up of 32 months.
At multivariate analysis, RFP (hazard ratio [HR], 4.16; 95%
confidence interval [CI], 1.54–11.23; P=.005) and New York
Heart Association class III or IV (HR, 2.15; 95% CI, 1.33–
3.47; P=.001) were the independent predictors of poor
prognosis, and there was no statistically significant interac-
tion between LV dilation and RFP. Moderate ⁄ severe MR
was associated with poorer outcome in the group of
patients with normal volumes, whereas it was not a signifi-
cant predictor of mortality in patients with any degree of
LV dilation. In patients with nonischemic HF, RFP is the
most important indicator of poor prognosis, irrespective of
the degree of LV dilation. Normal LV volumes increase the
negative prognostic impact of moderate to severe MR.
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It has been known since the 1980s that patients
with heart failure (HF) as a result of dilated cardio-
myopathy may present with end-stage HF despite
having only mild left ventricular (LV) dilation.1–4
The clinical and prognostic significance of this find-
ing was found to vary. In fact, although a small left
ventricle might be considered an indicator of early
stage of disease, these patients generally exhibit
somewhat poorer prognosis compared with those
with conventional dilated cardiomyopathy.1,2 From a
pathophysiologic point of view, it is reasonable to
hypothesize that a smaller forward cardiac output
due to the small LV volumes might increase the neg-
ative prognostic impact of a restrictive LV filling
pattern (RFP) and ⁄or moderate to severe mitral
regurgitation (MR).5–8 A collaborative group, the
Meta-analysis Research Group in Echocardiography
(MeRGE), was recently established to test the inde-
pendent prognostic significance of RFP in patients
after acute myocardial infarction and in patients
with HF.9,10 Using the large dataset provided by this
collaborative group, we sought to evaluate the prog-
nostic implications of LV size and the interplay
between LV size, LV filling, and MR in patients
with nonischemic HF.
METHODS
Study Design
The MeRGE HF study design has been previously
described in detail.9 Briefly, prospective studies that
enrolled consecutive HF patients and included compre-
hensive echocardiography and outcome data were
identified through online searches of several medical
databases and through personal communication. Using
a standard systematic review approach,9 all prospec-
tive outcome studies in HF patients that included com-
prehensive echocardiographic assessment of diastolic
filling were identified and the investigators were
invited to submit their individual patient databases to
a central site. Data were checked for consistency,
range checks were performed, and clustering by the
individual sites was evaluated. Overall, the MeRGE
HF study encompasses more than 80% of the avail-
able prospective data that included comprehensive
echocardiographic data as well as outcome data in
well-characterized HF patients and demonstrated that
RFP was associated with a 2-fold increase in the risk
of death independently of LV ejection fraction
(LVEF).10
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Patients
The present analysis was restricted to patients with
HF of nonischemic etiology and it includes data from
10 prospective studies (9 published6,11–18 and 1
unpublished) with quantitative LV volume analysis
and grading of mitral regurgitation. In such studies,
ischemic heart disease was diagnosed on the basis of
documented previous myocardial infarction or of sig-
nificant coronary artery disease on coronary arterio-
graphy, and nonischemic heart disease was diagnosed
in all other cases. Wall motion abnormalities were
never considered a marker of ischemic heart disease.
All patients with nonischemic HF were included, except
in cases where the primary cause was valvular heart dis-
ease. Since this is a study of diastolic function, patients
with atrial fibrillation ⁄flutter or a paced rhythm were
also excluded. In addition, none of the studies enrolled
patients with specific restrictive cardiomyopathies such
as cardiac amyloidosis. The individual patient data
from each study were merged into a single database
(demographic, clinical, echocardiographic, and out-
come). Patients were recruited and echocardiography
was performed in stable outpatients or at the time of
hospital discharge in inpatients.
Echocardiography
The definition of LVRFP is a dichotomous variable
based on the individual site definition (based on high
E:A ratio and shortened deceleration time) (n=351) or
by a predetermined cut-off value for transmitral
E-wave deceleration time (<140 ms) (n=250). LV
function variables included in the study were end-dia-
stolic and end-systolic volume, LV ejection fraction
(LVEF) and the degree of MR as graded by the indi-
vidual site using a combination of visual assessment
and quantitative methods. LVEF was estimated using
validated quantitative methods (Simpson biplane
method of discs or area-length method).
Statistical Methods
All data were collected and analysed by the MeRGE
Coordinating Centre at the University of Auckland.
The primary end point was all-cause death (or cardio-
vascular death where all-cause death was unavailable).
All-cause death was the primary end point in a total
of 430 patients and cardiovascular death was the pri-
mary end point in 171 patients. The Cox proportional
hazard model, stratified by study, was used to investi-
gate the univariate association of RFP and outcome as
well as to determine independent predictors of mortal-
ity in all patients from: RFP, LV end-diastolic volume
(LVEDV), LV end-systolic volume (LVESV), age, sex,
New York Heart Association (NYHA) class, and the
interaction of RFP and LVEDV. Patients were divided
into different groups according to the sex-specific lim-
its for LVEDV suggested by the American Society of
Echocardiography (ASE).19 Group 1 included patients
with normal volumes (ASE group 1). Group 2
included patients with either mild or moderate dilation
(ASE groups 2 and 3). Group 3 included patients with
severe LV dilation (ASE group 4). Kaplan-Meier sur-
vival analyses comparing RFP vs non-RFP for each LV
volume group were performed and the Cox propor-
tional hazards model was reapplied within each
volume group, this time omitting LVEDV and the
interaction term from the model. As the subset of
patients with information on MR was relatively small
and a potential interaction between MR and volume
was of interest, a Cox proportional hazards model,
stratified by study, was performed that contained
LVEDV categorized as normal (ASE group 1) or
dilated (ASE groups 2, 3, or 4), MR categorized as
none ⁄mild or moderate ⁄ severe, and the interaction
between MR and volume. Kaplan-Meier survival
analyses comparing moderate ⁄ severe MR with
normal ⁄mild MR within each of the two LV volume
groups were also performed. Procedures of SAS v9.1
(SAS Institute, Cary, NC) were employed. A P value
<.05 was considered significant.
RESULTS
A total of 601 patients were included. The clinical
characteristics of the study population as a whole and
across LVEDV-based groups are shown in Table I.
The average age of the patients was 56 years, approxi-
mately three quarters were men, and mean LVEF was
27%. RFP was present in 251 patients (42%). These
patients were not different from the main MeRGE
cohort of patients with HF from which they were
selected. According to the sex-specific limits for
LVEDV suggested by the ASE, 97 patients (16%) had
normal volumes (group 1), 98 patients (16%) had
mild or moderate LV dilation (group 2), and 404
patients (68%) had severe LV dilation (group 3). Age,
EF, E ⁄A ratio, deceleration time of mitral inflow, and
the proportion of RFP and death were similar in all
groups, but there was a greater proportion of women
in group 3 (Table I). In a subset of 252 patients, infor-
mation was available on the degree of MR at echocar-
diography. As shown in Table II, the characteristics of
these patients were similar to those of the entire popu-
lation, with the exception of younger age.
Survival
During a median follow-up period of 32 months, 106
deaths occurred: 67 (27%) in the RFP group and 39
(11%) in the non-RFP group (univariate hazard ratio
[HR], 2.99; 95% confidence interval [CI], 1.98–4.51).
Prognostic Indicators According to LV Dilation
In the whole population, the univariate HR of RFP
tended to be greater in patients with normal end-
diastolic volumes (HR, 8.3; 95% CI, 2.1–32.6)
(Figure 1A) than in patients with mild to moderate (HR,
3.0; 95% CI, 1.1–8.3) (Figure 1B) or severe dilation
(HR, 2.3; 95% CI, 1.4–3.7) (Figure 1C). However, at
multivariate analysis, RFP (HR, 4.16; 95% CI, 1.54–
11.23; P=.005) and NYHA III or IV (HR, 2.15; 95%
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CI, 1.33–3.47; P=.001) were the only independent pre-
dictors of poor prognosis and the interaction between
LVEDV and RFP was not statistically significant in the
model (Table III). In the subset of 252 patients with
information on the degree of MR, moderate ⁄ severe MR
was associated with poorer outcome in the group of
patients with normal volumes (n=60; univariate HR,
12.1; 95% CI, 1.4–101) (Figure 2A), whereas it was not
a statistically significant predictor of mortality in
patients with dilation (n=191; univariate HR, 0.6; 95%
CI, 0.3–1.4) (Figure 2B). At multivariate analysis, RFP
(HR, 4.6; 95% CI, 2.1–10.4; P=.0002), LV dilatation
(HR, 6.01; 95% CI, 1.16–32.2; P=.04), and the interac-
tion between LVEDV and moderate ⁄ severe MR (HR,
0.17; 95% CI, 0.03–0.97; P=.046) were statistically sig-
nificant (Table IV).
DISCUSSION
The present study shows that the degree of LV dilation
is not per se a determinant of prognosis in patients
with nonischemic HF. However, we noticed that LV
dilation interacts with other LV functional parameters,
indirectly impacting prognosis. The risk associated
with moderate ⁄ severe MR was in fact significant only
in patients with normal LVEDV, and the risk associ-
ated with RFP tended to be higher, albeit nonsignifi-
cantly, in patients with normal end-diastolic volumes
than in those with mild to moderate or severe LV dila-
tion. These findings are particularly important since
patients with small LV cavities might be thought to
have less advanced disease, whereas they indeed have
similar prognosis as patients with dilated LV cavities,
and especially so in the presence of restrictive filling.
Different Presentation of LV Dilation in Patients
With Nonischemic HF
In the present study, a wide spectrum of LV size was
observed among patients with nonischemic HF, with a
substantial proportion (24%) having either normal
sex-specific LVEDV or mild LV dilation. Such a high
prevalence of patients with mildly dilated cardio-
myopathy is remarkably similar to that reported in
previous small single-center studies, suggesting that
it could be an intrinsic characteristic of about one
TABLE II. Clinical and Echocardiographic Characteristics of the Patients with Information on the Degree of MR
All Patients
N=252
Group 1
(Normal EDV) n=60
Group 2 (Mild to
Moderate Dilation) n=47
Group 3
(Severe Dilation) n=144
Age, y (meanSD) 48.214.3 53.912.3 48.813.2 45.614.9
Male, n (%) 199 (79) 57 (95) 42 (89) 100 (69)
NYHA I ⁄ II ⁄ III ⁄ IV, n 24 ⁄ 120 ⁄ 91 ⁄ 17 6 ⁄ 40 ⁄ 10 ⁄ 4 9 ⁄ 18 ⁄ 18 ⁄ 2 9 ⁄ 62 ⁄ 63 ⁄ 10
EF, % 25, 20–30 25, 19–30 27, 22–31 25, 19–29
LVEDV, mL 201, 147–285 123, 100–144 173, 162–187 277, 221–325
LVESV, mL 148, 111–212 94, 71–107 128, 118–136 200, 161–251
E ⁄ A ratio 1.3, 0.8–2.5 1.2, 0.7–1.9 1.8, 0.9–3.0 1.4, 0.8–2.6
DT, ms 121, 90–170 150, 110–183 140, 90–170 110, 85–150
RFP, n (%) 138 (55) 26 (43) 23 (49) 89 (62)
Deaths, n (%) 46 (18) 9 (15) 9 (19) 28 (19)
Abbreviations: NYHA, New York Heart Association; HT, hypertensive; EF, ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left
ventricular end-systolic volume; E ⁄ A, ratio of early to late left ventricular filling waves; DT, deceleration time of E wave; RFP, restrictive filling pattern.
TABLE I. Clinical and Echocardiographic Characteristics in the Whole Population and According to LV Dilation
All Patients
N=601
Group 1
(Normal EDV) n=97
Group 2 (Mild to
Moderate Dilation) n=98
Group 3
(Severe Dilation) n=404
Age, y (meanSD) 55.515.3 59.414.9 57.615.9 54.015.1
Male, n (%) 442 (74) 84 (87) 81 (83) 277 (69)
NYHA I ⁄ II ⁄ III ⁄ IV, n 75 ⁄ 263 ⁄ 220 ⁄ 32 12 ⁄ 56 ⁄ 22 ⁄ 5 15 ⁄ 40 ⁄ 37 ⁄ 6 48 ⁄ 166 ⁄ 161 ⁄ 20
Aetiology (DCM ⁄ HT ⁄ othera), n 548 ⁄ 36 ⁄ 17 82 ⁄ 8 ⁄ 6 86 ⁄ 10 ⁄ 3 378 ⁄ 18 ⁄ 8
EF, % 27, 21–33 30, 23–35 28, 22–33 25, 20–32
LVEDV, mL 211, 157–287 123, 98–144 173, 160–188 255, 210–313
LVESV, mL 149, 111–217 87, 65–104 127, 106–137 188, 142–242
E ⁄ A ratio 1.2, 0.7–2.1 1.2, 0.6–1.9 1.5, 0.8–2.8 1.2, 0.7–2.1
DT, ms 150, 110–209 150, 115–200 150, 110–203 150, 110–210
RFP, n (%) 251 (42) 38 (39) 44 (45) 169 (42)
Deaths, n (%) 106 (18) 15 (15) 20 (20) 71 (18)
Abbreviations: DCM, dilated cardiomyopathy; HT, hypertensive; EF, ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left ven-
tricular end-systolic volume; E ⁄ A, ratio of early to late left ventricular filling waves; DT, deceleration time of E wave; RFP, restrictive filling pattern.
Continuous variables are presented as median, IQR unless otherwise stated. aOther indicates mixed or undefined aetiology.
Congest Heart Fail Vol. ** | No. * | *** 2012 3
prognostic implications of left ventricular dilation | Ghio et al.
quarter of patients with nonischemic HF.3,4 Whether
mild LV dilation depends on specific biologic charac-
teristics of the disease is as yet unknown. Previous
studies have attempted to utilize myocardial biopsy
data to clarify this issue without success, and genetic
data are not available at present.1,2
Echocardiographic Predictors of Prognosis
in Patients With Nonischemic HF
In the present population of nonischemic HF patients,
RFP of the left ventricle was the strongest echocardio-
graphic indicator of poor prognosis. This confirms the
results of several important studies that concluded that
RFP is the most important predictor in chronic HF
patients with different etiologies.5,6,18 On the contrary,
the degree of LV dilatation and LVEF were not inde-
pendent predictors of mortality. This observation is
seemingly in contrast to the notion that the beneficial
effects of renin-angiotensin-aldosterone system inhibi-
tors and b-blocking agents in HF patients are in great
part mediated by drug effects on LV volumes and
function. In the Studies of Left Ventricular Dysfunc-
tion (SOLVD) echocardiographic substudy,20 enalapril
significantly reduced EDV and ESV over 12 months as
compared with placebo. Carvedilol has been shown to
reduce volumes and increase EF in the echocardio-
graphic substudy of the Australia-New Zealand Heart
Failure Research Collaborative Group.21 The Valsar-
tan Heart Failure Trial (Val-HeFT) echocardiographic
substudy22 showed a reduction in LV end-diastolic
dimensions and an increase in EF during treatment
with valsartan as compared with placebo. In the Study
of the Effects of Nebivolol Intervention on Outcomes
and Hospitalization in Seniors With Heart Failure
(SENIORS) echocardiographic substudy,23 LVESV
decreased and EF increased after 12 months of therapy
with nebivolol. Although these studies convincingly
showed that pharmacotherapy can have favorable
effects on LV remodeling in patients with HF and
that reverse remodeling is associated with improved
TABLE III. Multivariable Predictors of Outcome
Characteristic Hazard Ratio
95% Confidence
Interval P Value
All patients (n=594)
RFP 4.16 1.54–11.23 .005
LVEDV, mL 0.998 0.988–1.01 .62
LVESV, mL 1.01 0.997–1.02 .14
Age, y 1.01 0.997–1.03 .11
Gender, male 1.10 0.67–1.80 .71
NYHA III or IV 2.15 1.33–3.47 .001
RFP*LVEDV 0.997 0.994–1.00 .13
Abbreviations: RFP, restrictive filling pattern; LVEDV, left ventricular
end-diastolic volume; LVESV, left ventricular end-systolic volume;
NYHA, New York Heart Association; RFP*LVEDV, interaction
between RFP and LVEDV.
FIGURE 1. Kaplan-Meier survival curves in patients with restrictive filling pattern (RFP) (continuous line) or without RFP (dashed line) for each
volume category. See text for statistical significance. (A) Patients with normal left ventricular (LV) end-diastolic volumes. (B) Patients with mild to
moderate LV dilation. (C) Patients with severe LV dilation.
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survival, much less attention has been paid to the ori-
ginal relationship between LV geometry, systolic and
diastolic function, and outcome. The influence of
LVEF on cardiovascular outcomes was evaluated in
the Candesartan in Heart Failure Reduction in Mortal-
ity (CHARM) program,24 but no further volumetric
data or other echocardiographic prognostic parameters
were available. The only study that included data on
LV volume, LV filling, and degree of MR was the
b-Blocker Evaluation of Survival Trial (BEST),25 which
found LVEDV to be an independent predictor of prog-
nosis. Furthermore, most of these studies enrolled
patients with HF of both ischemic and nonischemic
etiology. Thus, the issue of the prognostic role of LV
dilation in patients with nonischemic HF has not yet
been fully addressed in large trials. One could hypoth-
esize that improvements in LV geometry and function
due to medical therapy have positive effects on prog-
nosis regardless of the degree of LV dilatation and
dysfunction at baseline. In addition, it could be argued
that patients with mild LV dilatation may be miscon-
strued as being in the early stage of disease and be
denied therapy with a clinically important negative
outcome.
Although the degree of LV dilation was not per se a
determinant of prognosis in this series of patients with
nonischemic HF, we noticed that LV dilation interacts
with mitral regurgitation, indirectly impacting progno-
sis. In the subset of patients in whom a quantification
of the degree of MR was available, moderate ⁄ severe
MR was found to be a significant predictor of mortal-
ity in those with normal volumes but not in those with
LV dilation. These findings could be explained consid-
ering that, for any degree of MR volume, the reduc-
tion of stroke volume is greater in patients with
normal LV volumes than in patients with dilated
hearts. Additionally, although the risk associated with
an RFP was not statistically different among patients
with different LVEDV, it tended to be greater in
patients with normal sex-related LVEDV than in
patients with mild to moderate dilation and even
lower in patients with severe dilation. The reason
might be that a normal-sized LV has to contend with
greater wall stress compared with a dilated LV in the
presence of RFP, ie, of elevated filling pressures. This
may induce greater neurohormonal activation and sub-
sequent poorer prognosis. The findings of the present
study have relevant clinical implications, since patients
with nonischemic HF and small LV cavity size might
be considered at lower risk, whereas they might need
more aggressive therapy to revert an LVRFP pattern
and to reduce the degree of MR.
Limitations
The present analysis includes only part of the original
MeRGE database, since the entry criteria here were
restricted to patients with nonischemic etiology and
systolic LV dysfunction. We also acknowledge the lack
of quantitative grading of MR and the relatively small
number of patients in the MR subanalysis. In addition,
prognosis in HF patients is related to many clinical
factors that could not be considered in the present
meta-analysis.26 These limitations partly relate to the
way in which the data were collated; for example,
quantitative MR data were not an entry criterion of
the main MeRGE HF study, so that when considering
MR, we were only able to compare none ⁄mild vs
moderate ⁄ severe MR. The main MeRGE database has
some limitations also. In order to gather as many data
TABLE IV. Multivariable Predictors of Outcome in
Subset with Information on the Degree of MR, n=251
Characteristic
Hazard
Ratio
95% Confidence
Interval P Value
Restrictive filling pattern 4.6 2.1–10.4 .0002
Dilated LVa 6.01 1.12–32.2 .04
Moderate ⁄ severe MR 2.84 0.57–14.2 .20
Moderate ⁄ severe MR*dilated LV 0.17 0.03–0.97 .05
Abbreviations: LV, left ventricle; MR, mitral regurgitation. aAny
degree of dilatation above ASE normal reference range.
FIGURE 2. Kaplan-Meier survival curves in patients with moderate to severe mitral regurgitation (MR) (continuous line) or absent to mild MR
(dashed line) for each volume category. See text for statistical significance. (A) Patients with normal left ventricular (LV) end-diastolic volumes.
(B) Patients with any LV dilation.
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(and events) as possible, some compromises were
made. We do not have extensive clinical data (such as
etiology, treatment, prior admissions) and we
acknowledge that many of these parameters may con-
tribute to mortality in these patients. However, inclu-
sion in a multivariable model of all relevant data with
known prognostic impact in HF patients would be an
extremely challenging objective. Nevertheless, we feel
that the omission of these data is partially balanced by
the large sample size and number of events when com-
pared with previous studies in this area. We have used
two different end points in this study: all-cause death
and cardiovascular death, in order to increase the
available sample size. These are both very common
end points in HF studies, and other studies have
shown that <10% of deaths in HF patients are non-
cardiovascular,27 and in our study only 171 (28%)
patients originated from studies with total mortality
data only, and since our overall number of deaths was
106 (18%), we estimate that the number of additional
deaths that might have been included in this group
could be no more than 2 to 4 events. Finally, with a
few exceptions, patients in the general population dif-
fer from those enrolled in HF trials usually by being
older and more frequently having a preserved LV func-
tion.28 This is a limitation that also applies to the
present meta-analysis. There may be slight differences
in both HF and echocardiographic diagnostic algo-
rithms between sites. We used the original definition
of RFP at the recruiting hospital, and while there may
have been subtle differences in the definition of RFP,
the methods were all well accepted in both the litera-
ture and clinical practice and reflect normal variation
in clinical practice.
CONCLUSIONS
Although patients with HF and small LV cavities
might be anticipated to be those with less advanced
disease, they have a similar prognosis as patients with
dilated hearts, and especially so in the presence of
restrictive LV filling. In fact, the risk associated with
RFP tended to be slightly, albeit not significantly,
higher in patients with normal end-diastolic volumes
than in patients with LV dilation. Interestingly, LV
cavity size indirectly impacts the relationship between
prognosis and moderate to severe MR. In addition,
MR was not a significant predictor of outcome in
patients with dilated LV cavities. These findings sup-
port the integration of several echocardiographic
parameters, including diastolic parameters, LV vol-
umes, and the severity of MR, for predicting outcome
in individual patients with HF.
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